成都专科精索静脉曲张科医院成都有哪些治疗老烂腿的医院,成都鲜红斑痣哪家较好,成都治疗静脉曲张大概费用多少钱,成都治睾丸精索静脉曲张医院哪个好,成都怎样才能治好前列腺肥大,成都哪里有看老烂腿,成都医院治前列腺肥大

In an old traditional historic church building sits a seemingly nontraditional religion."We don’t pretend that we’ve invented something new; we just gave it a title and a safe place for people to use cannabis in their spiritual journeys to come here, and worship, and pray,” said co-founder Steve Berke. “We don’t tell them who to pray to. It’s really an open-minded spiritual community."Their religion is Elevationism. Berke says it's about elevating one's self to the best version of self."While we do believe that cannabis can help you on your way to your spiritual journey, it’s also okay if you don’t use cannabis," said Berke.He says they have people all over the world come to their church. People of all political views, races, and even other religious beliefs have joined their congregation."Elevationism is not a replacement to your existing faith. It’s more of a supplement to it. You can be a Christian and an Elevationist. You can be Jewish and an Elevationist. You can be a Buddhist and an Elevationist," said Berke.Before COVID-19, like any other church, they would hold a Sunday service in their sanctuary with speakers, music, and lessons to take away. But unlike a traditional church, the consumption of cannabis was allowed."We certainly encourage people to try cannabis, and if it doesn’t work for you, that’s OK. You don’t have to use cannabis. We don’t tell you when to use it. We don’t tell you how much to use it," said Berke.Since the pandemic, they’ve had to stop the Sunday service but have continued with their daily BEYOND, a guided meditation paired with a light show. It’s family-friendly, no consumption allowed, and open to the public."Everybody takes something different from the meditation and that’s the goal. The goal is some people will take one quote of that mediation and apply it to their lives," said Berke.And just like any other church, Berke says they give back to their community."We’ve led by example. We’ve volunteered picking up trash in the neighborhood, volunteering at animal shelters, feeding the homeless. We do all of the things that a normal church does without preaching a dogma inside our church," said Berke.For now, they have one location in Denver but plan to expand to Los Angeles next year. They're also working on more guided meditations."We’ll have BEYOND Happiness, BEYOND love, BEYOND doubt, so all these different themes encouraging people to think and question existing establishment thought and really encourage their spiritual paths and journeys," explained Berke.Berke says the one golden rule of their ministry is similar to other traditional religions: treat others the way you want to be treated."We’re all one human race. We may have different beliefs. We may believe in different gods, but that’s okay, right? Because we’re all spiritual and we all ultimately want this world to be a better place for the next generations," said Berke. 2920

How accurate are the coronavirus tests used in the U.S.?Months into the outbreak, no one really knows how well many of the screening tests work, and experts at top medical centers say it is time to do the studies to find out.When the new virus began spreading, the Food and Drug Administration used its emergency powers to OK scores of quickly devised tests, based mainly on a small number of lab studies showing they could successfully detect the virus.That’s very different from the large patient studies that can take weeks or months, which experts say are needed to provide a true sense of testing accuracy.The FDA’s speedy response came after it was initially criticized for delaying the launch of new tests during a crisis and after the Centers for Disease Control and Prevention stumbled in getting its own test out to states.But with the U.S. outbreak nearly certain to stretch on for months or even years, some experts want the FDA to demand better evidence of the tests’ accuracy so doctors know how many infections might be missed.There have been more than 2 million confirmed coronavirus cases in the U.S. and more than 115,000 deaths, according to data compiled by Johns Hopkins University. Cases in nearly half of U.S. states are rising.In recent weeks, preliminary findings have flagged potential problems with some COVID-19 tests, including one used daily at the White House. Faulty tests could leave many thousands of Americans with the incorrect assumption that they are virus-free, contributing to new flare-ups of the disease as communities reopen.“In the beginning, the FDA was under a lot of pressure to get these tests onto the marketplace,” said Dr. Steven Woloshin of Dartmouth College, who wrote about the issue in the New England Journal of Medicine last week. “But now that there are plenty of tests out there, it’s time for them to raise the bar.”The FDA said in a statement that it has already asked multiple test makers to do follow-up accuracy studies, although it didn’t say for how many of the more than 110 authorized screening tests. The agency also said it is tracking reports of problems. Accuracy has also been an issue with blood tests that look for signs of past infections.No screening test is 100% accurate. So details on accuracy are routinely provided for tests of all types, including seasonal flu, hepatitis, HIV and cancers. For example, rapid flu tests are known to miss 20% or more of all cases, a factor doctors weigh when treating patients who have symptoms but test negative.For now, most COVID-19 tests in the U.S. don’t give data on real-world performance, including how often the tests falsely clear patients of infection or falsely detect the virus. That information is lacking for all but a few of the roughly 80 commercial screening tests available, according to an Associated Press review.The government’s emergency authorization process “requires a lower level of evidence,” the agency said. Makers need only show that a test “may be effective” instead of the usual requirement to demonstrate “safety and effectiveness.” They would have to meet that higher threshold once the U.S. government declares the emergency over.Many of the commercial test makers submitted results from 60 samples, the minimum number required and mostly used lab-produced specimens of the virus. The FDA now recommends the use of nasal swabs or other real samples from people screened for coronavirus.Experts say larger patient studies patients are needed to assess a test’s true performance.Lab testing bears little resemblance to actual — sometimes imperfect — conditions at hospitals, clinics and testing sites noted Dr. Robert Kaplan of Stanford University.“You’re testing people in parking lots, the patients themselves are extremely anxious and often unable to follow instructions,” said Kaplan, a former associate director of the National Institutes of Health.Kaplan and others say those differences could explain why some tests are not performing as expected.Last month, the FDA warned doctors of a potential accuracy problem with Abbott Laboratories’ rapid ID Now test, which delivers results in roughly 15 minutes. The test has been lauded by President Donald Trump and used to screen the president, his staff and visitors to the White House.The FDA alert followed a preliminary report by New York University that found Abbott’s test missed between a third to one-half of infections caught by a rival test in patients screened for the virus.Abbott rejected the findings, saying the researchers did not follow the instructions for using its test. The company pointed to alternate patient studies, including its own, that have found the test successfully detects between 91% and 95% or more of virus cases when compared to other tests.But similar problems with ID NOW’s accuracy have been flagged in preliminary reports by researchers at Stanford University, Loyola University and the Cleveland Clinic.For now, the FDA is requiring Abbott to conduct follow-up studies in several different patient groups.The FDA’s emergency standards “are still high but there is a significant difference in the body of work that what would go into a submission under the normal process,” said Abbott vice president John Hackett. “Our normal process takes years to bring these out.”Requiring bigger studies of all coronavirus tests could provide valuable information, but it could also strain the FDA’s already stretched staff and resources, said Dr. Daniel Schultz, former director of the FDA’s medical device center.Dr. Colin West of the Mayo Clinic worries doctors and patients have put too much confidence in the current crop of tests, when an unknown number of patients with COVID-19 are likely receiving false negative results.Even a modest error rate can have grave consequences during an outbreak like COVID-19. West gives the example of a test that is 95% accurate at detecting the virus and is used on 1 million people. That would still result in 50,000 people being incorrectly told that they don’t have the virus.“The negative test does not mean that I’m off the hook,” West said. “We just need to maintain that level of vigilance until we have a better sense of how good these tests really can be.”___Follow Matthew Perrone on Twitter: @AP_FDAwriter.___Follow AP pandemic coverage at http://apnews.com/VirusOutbreak and https://apnews.com/UnderstandingtheOutbreak.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6604

In Bucks County, Pennsylvania, prosecutors are arguing that 30-year-old Samantha Jones killed her 11-week-old son, R.J., by breastfeeding while using drugs.According to the criminal complaint, R.J. died from ingesting a "combination of fatal drugs through breast milk" and is being charged with criminal homicide.Jones' attorney, Louis Busico, said that Jones "absolutely, unequivocally loved that child" and never intended to harm him.According to an affidavit, Jones told investigators that about 3 a.m. April 2, she heard R.J. crying.He had been primarily breastfed, Jones said, but she had recently started using formula because she worried that he wasn't getting enough milk and wasn't sleeping. She was too tired to make a bottle of formula, according to the affidavit, so she decided to nurse him. She then dozed on and off for a few more hours.Before her husband, Vincent McGovern, left for the day, he made R.J. a bottle and left it with Jones. She remembers feeding R.J., putting him back in his bassinet around 6:30 a.m. and going back to sleep.In the affidavit, Jones said she woke up about an hour later and panicked when she saw that R.J. was pale and had bloody mucus coming out of his nose. Jones and her mother, who also lived in the house, called 911 and began CPR.R.J. was taken to a hospital by ambulance and pronounced dead by 8:30 a.m.According to the Bucks County Coroner's Office, the autopsy revealed traces of methadone, amphetamine and methamphetamine were found in the infant's blood and contributed to his death.The affidavit further noted that the examiner who performed the autopsy said "R.J. ingested the combination of fatal drugs through breast milk."According to the affidavit, Jones told the investigators that she had been prescribed methadone since pregnancy to help manage her addiction to opioid painkillers, but there is no mention of other drugs.Investigators say they tested the bottle last used to feed R.J., as well as the can of formula, and found no traces of illicit drugs.In a news release, Bucks County Deputy District Attorney Kristin M. McElroy said it is possible that Jones could face a murder charge that carries a mandatory life sentence. The prosecutor's office did not offer any additional comment.Since her arrest, Busico said, his client is "completely in a state of depression." He added that the charges and arrest kicked Jones when she was already down, dealing with the death of her child.When asked about amphetamine or methamphetamine drug use by Jones, Busico would not comment.Jones' preliminary hearing was set for Wednesday. Through her attorney, she declined to speak with CNN. 2666

House Speaker Paul Ryan called allegations leveled against Alabama Republican Senate candidate Roy Moore about pursuing relationships with teenage girls and committing sexual assault "credible" and that he should step aside."He should step aside," Ryan told CNN Tuesday morning. "Number one, these allegations are credible. Number two, if he cares about the values that he claims to care about, then he should step aside."Ryan becomes the latest high-profile Republican voice to call on Moore to step aside, following more than two dozen Republican senators, including some of whom have suggested voting to expel Moore from the Senate should he win the December 12 special election.The flood of condemnation and calls to step down replaced what had been days of heavily caveated statements defined by senators calling for Moore to step aside "if" the allegations "were true." Starting Monday with Ryan's counterpart, Senate Majority Leader Mitch McConnell, the tone from national Republicans shifted dramatically.An Alabama woman alleged Monday that Moore sexually assaulted her when she was a teenager. Moore called the accusation "absolutely false" in a statement in Gallant, Alabama, later Monday, denying that he knew the woman.The accusations came after The Washington Post published a report last week based on interviews with more than 30 people, saying Moore pursued relationships with teenagers while he was in his 30s. One woman said she was 14 years old when Moore initiated sexual contact with her. Moore also denied those allegations and has threatened to sue the Post.For now, GOP leaders are stuck in an increasingly difficult position. Moore has repeatedly said he has no intention of stepping down and views the stories themselves -- and the GOP senators that have condemned him in its wake -- are nothing but political attacks. Senate Republicans made clear they are weighing several options on how to go forward, ranging from pushing for a write-in campaign to trying to vote Moore out of the Senate should he win.One Republican senator, Jeff Flake, the Arizonan who announced last month he would retire at the end of his term, became the first to present another choice Monday night: support Moore's opponent."If the choice is between Roy Moore and a Democrat, a Democrat no doubt," Flake told reporters.  2338

I am extremely disappointed in the passage of this punitive, short-sighted ordinance. Believing that ticketing and incarcerating homeless individuals will motivate them to pursue other options is naive and cruel. We will continue to advocate for the rights of the homeless to access public spaces and defend their civil liberties whenever any government seeks to restrict them. 385